Fig. 10
From: cRGD-based MRI imaging-enhanced nanoplatform helps DOX target pancreatic cancer
In vivo T1 imaging of nano-loaded drug platforms. (A) Changes in T1 signal intensity at cHDG@MSN tumor site injection, (B) Pseudo-color image of injected cHDG@MSN tumor site, (C) Changes in T1 signal intensity at the site of injected HDG@MSN tumors, (D), (E) In vitro changes with different concentrations of cHDG@MSN and its signal intensity, (F) In vitro with different concentrations of gadopentetate dextran and changes in signal intensity.
